Lynn Seely

Lynn Seely, M.D. has served as a member of the board of directors since May 2021. Dr. Seely currently serves as a member of the board of directors of Blueprint Medicines Corp., a publicly-traded pharmaceutical company focused on precision medicine. From June 2016 to January 2021, Dr. Seely served as President, Chief Executive Officer and a member of the board of directors of Myovant Sciences, a biotechnology company, focused on redefining care for women and for men by developing and commercializing innovative therapies such as ORGOVYX (relugolix) for men with advanced prostate cancer. From March 2005 to October 2015, Dr. Seely served as Senior Vice President and Chief Medical Officer of Medivation, a biotechnology company, where she led the development of XTANDI (enzalutamide) from the first-in-human clinical trial through global approvals for men with castration-resistant prostate cancer. Dr. Seely received an M.D. from the University of Oklahoma College of Medicine and a B.A. in Journalism from the University of Oklahoma. Dr. Seely completed her residency and served as chief resident in internal medicine at Yale-New Haven Hospital, and she completed her fellowship in endocrinology and metabolism at the University of California, San Diego.